Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LP-005 in Paroxysmal Nocturnal Hemoglobinuria
NCT07266155Phase 2Not yet recruiting
- Sponsor
- LongBio Pharma
- Start
- Dec 2025
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of LP-005 in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by LongBio Pharma. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
LP-005
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT07266155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07266155.